GMAB

Genmab A/S American Depositary Shares (GMAB) | Rumor.io

Genmab A/S

GMAB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,772

Bullish sentiment (50-day avg)88%

Price to earnings ratio28.2

Market capitalization21.7B

Earnings per share1.26

Dividend yield (TTM)—

Revenue (annual)3.7B

Net income (annual)963M

Social

What share of all stock conversation is about GMAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 30

Genmab A/S (GMAB) announced positive Phase 3 results for Epcoritamab plus Lenalidomide in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma, showing a 60% reduction in progression/death risk.
The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival, with potential to challenge CAR-T therapies.
The stock has surged 8.69% pre-market, with analysts optimistic about the upcoming Epcore DLBCL-2 trial readout for Epkinly in first-line DLBCL, and a potential buyout at $50-60.

Generated by AI

Sentiment

Of the messages about GMAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	66.67% -30.65	93.17% -4.12
Bearish	—	0% 0	33.33% +30.65	6.83% +4.12

Sep 29

Genmab's acquisition of Merus is expected to boost growth, with a potential drug launch by 2027, driven by the late-stage cancer drug petosemtamab with two FDA breakthrough designations.
The acquisition is seen as a validation of Merus' technology, with the company's shares surging 38% and its market value increasing by 35.97% in a single day.
The deal is expected to drive Genmab shares higher, with analysts predicting a potential 16% jump to $34, and could also create sector momentum in biotech and cancer drug development.

Generated by AI

Topics

Of the messages about GMAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	63.16%	52.98%	40.33%
Technical Analysis	—	0%	8.61%	3.39%
Analysts	—	36.84%	27.15%	12.48%
Macro	—	0%	11.26%	35.73%
Controversies	—	0%	0%	0.76%
Earnings	—	0%	0%	7.31%

Sep 29

Genmab A/S (GMAB) is acquiring Merus (MRUS) for $8 billion in an all-cash transaction, valuing MRUS at $97 per share.
The deal brings in petosemtamab, a late-stage cancer drug with two FDA breakthrough designations, and is expected to boost Genmab's growth with a potential drug launch by 2027.
The acquisition represents a 41% premium to Merus' prior close, and Genmab expects to accelerate its shift into a global biotech leader through this deal.

Generated by AI

Community

Of the messages about GMAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	95.35%	68.9%	46.88%
Newcomers	—	4.65%	31.1%	53.12%

Regulars· Oct 20

Genmab's flagship products are facing competitive headwinds, affecting its performance at ESMO25.
The company's stock price dropped 4% premarket ahead of the ESMO25 conference.
Genmab is considered the loser of ESMO25 due to its struggling products.

Newcomers· Nov 8

Newcomers to Genmab A/S are sharing articles that explain the company simply, indicating a desire to learn more about the asset.
Some users are discussing the asset's earnings and timing entries, suggesting they are focused on its performance and potential for investment.
The geopolitical and market risks associated with Genmab A/S are being discussed, highlighting concerns about its stability and potential impact on the market.

Generated by AI

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s vice president and head of investor relations. Carlsen said

3d agoYahoo Finance

Genmab Grants New Employee Restricted Stock Units and Warrants

Tipranks Press Release.

4d agoThe Globe and Mail

Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks

The consensus analyst Price Target fair value for Genmab has been adjusted to DKK 2,303.24 from DKK 2,453.79, pointing to a slightly lower central target level for the stock. Analysts link this change to a balance of confidence in Genmab’s pipeline, including Epkinly and other key assets, and caution around concentration risks, clinical assumptions and the impact of the reported $3.6b Darzalex patent cliff. As you read on, you will see how these moving pieces shape the evolving analyst...

6d agoYahoo Finance

Also Discussed

Investors talking about GMAB also mention

#	Name	Attention
1	MRUS - Merus N.V.	——
2	Zymeworks Inc.ZYME	0%0
3	BGNE - BeiGene, Ltd.	——
4	BPMC - Blueprint Medicines Corporation	——
5	Incyte Corp.INCY	0%new
6	SGEN - Seagen Inc.	——
7	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
8	Legend Biotech Corporation ADRLEGN	0%+0
9	Immatics N.V.IMTX	0%0
10	argenx SE American Depositary ReceiptARGX	0%0

Genmab A/S American Depositary Shares

Healthcare
Biotechnology

Genmab A/S American Depositary Shares represents ownership in Genmab A/S, a Denmark-based biotechnology company focused on developing antibody-based therapies. The company’s business centers on human antibody therapeutics for cancer and other serious diseases, with products and product candidates spanning oncology and selected additional therapeutic areas. Its portfolio includes approved and partnered medicines, as well as research programs built around proprietary antibody technologies such as DuoBody and HexaBody. Genmab works across discovery, development, and commercialization, collaborating with pharmaceutical partners to advance biologic treatments through the clinical and regulatory process. The company serves the global biopharmaceutical market and plays a role in supplying innovative immunotherapy and antibody platforms to healthcare providers and patients worldwide.

Website

Location

Carl Jacobsens Vej 30

Copenhagen, 2500

Denmark

Social

What share of all stock conversation is about GMAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 30

Genmab A/S (GMAB) announced positive Phase 3 results for Epcoritamab plus Lenalidomide in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma, showing a 60% reduction in progression/death risk.
The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival, with potential to challenge CAR-T therapies.
The stock has surged 8.69% pre-market, with analysts optimistic about the upcoming Epcore DLBCL-2 trial readout for Epkinly in first-line DLBCL, and a potential buyout at $50-60.

Generated by AI

Sentiment

Of the messages about GMAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	66.67% -30.65	93.17% -4.12
Bearish	—	0% 0	33.33% +30.65	6.83% +4.12

Sep 29

Genmab's acquisition of Merus is expected to boost growth, with a potential drug launch by 2027, driven by the late-stage cancer drug petosemtamab with two FDA breakthrough designations.
The acquisition is seen as a validation of Merus' technology, with the company's shares surging 38% and its market value increasing by 35.97% in a single day.
The deal is expected to drive Genmab shares higher, with analysts predicting a potential 16% jump to $34, and could also create sector momentum in biotech and cancer drug development.

Generated by AI

Topics

Of the messages about GMAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	63.16%	52.98%	40.33%
Technical Analysis	—	0%	8.61%	3.39%
Analysts	—	36.84%	27.15%	12.48%
Macro	—	0%	11.26%	35.73%
Controversies	—	0%	0%	0.76%
Earnings	—	0%	0%	7.31%

Sep 29

Genmab A/S (GMAB) is acquiring Merus (MRUS) for $8 billion in an all-cash transaction, valuing MRUS at $97 per share.
The deal brings in petosemtamab, a late-stage cancer drug with two FDA breakthrough designations, and is expected to boost Genmab's growth with a potential drug launch by 2027.
The acquisition represents a 41% premium to Merus' prior close, and Genmab expects to accelerate its shift into a global biotech leader through this deal.

Generated by AI

Community

Of the messages about GMAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	95.35%	68.9%	46.88%
Newcomers	—	4.65%	31.1%	53.12%

Regulars· Oct 20

Genmab's flagship products are facing competitive headwinds, affecting its performance at ESMO25.
The company's stock price dropped 4% premarket ahead of the ESMO25 conference.
Genmab is considered the loser of ESMO25 due to its struggling products.

Newcomers· Nov 8

Newcomers to Genmab A/S are sharing articles that explain the company simply, indicating a desire to learn more about the asset.
Some users are discussing the asset's earnings and timing entries, suggesting they are focused on its performance and potential for investment.
The geopolitical and market risks associated with Genmab A/S are being discussed, highlighting concerns about its stability and potential impact on the market.

Generated by AI

Genmab A/S

Social

Jun 30

Sentiment

Sep 29

Topics

Sep 29

Community

Regulars· Oct 20

Newcomers· Nov 8

News

Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4

Genmab Grants New Employee Restricted Stock Units and Warrants

Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks

Genmab AS stock hits 52-week high at 35.48 USD

Genmab at bank of america global healthcare conference: late-stage push

Genmab at Morgan Stanley conference: pipeline widens, data loom

Also Discussed

Genmab A/S American Depositary Shares

Company Information

Location

News

Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4

Genmab Grants New Employee Restricted Stock Units and Warrants

Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks

Genmab AS stock hits 52-week high at 35.48 USD

Genmab at bank of america global healthcare conference: late-stage push

Genmab at Morgan Stanley conference: pipeline widens, data loom

Also Discussed

Social

Jun 30

Sentiment

Sep 29

Topics

Sep 29

Community

Regulars· Oct 20

Newcomers· Nov 8